Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retractable TechnologiesRVP 35 Debt-to-EBITDA is -0.10 as of Mar. 2026. GuruFocus rates RVP with a GF Score™ of 35/100 and a GF Value™ of $0.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Retractable Technologies ranks better than 68.31% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Retractable Technologies's Debt-to-EBITDA or its related term are showing as below:
RVP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.54 Med: -0.09 Max: 0.63
Current: 0.57
During the past 13 years, the highest Debt-to-EBITDA Ratio of Retractable Technologies was 0.63. The lowest was -10.54. And the median was -0.09.
RVP's Debt-to-EBITDA is ranked better than 68.31% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs RVP: 0.57
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Retractable Technologies Debt-to-EBITDA Related Terms
Retractable Technologies Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RVP vs ZJYL, HBIO, RGNT: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Retractable Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Retractable Technologies Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Retractable Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Retractable Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Retractable Technologies (RVP) has a Debt-to-EBITDA of -0.10 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Retractable Technologies. According to the industry distribution chart, Retractable Technologies ranks #148 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Retractable Technologies' Debt-to-EBITDA too high?
Retractable Technologies' current Debt-to-EBITDA is -0.10. Based on the distribution chart, Retractable Technologies ranks #148 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Retractable Technologies has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Retractable Technologies' Debt-to-EBITDA compare to ZJYL and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Retractable Technologies ranks #148 out of 467 companies for Debt-to-EBITDA. This puts Retractable Technologies in the upper half of its industry. The industry median Debt-to-EBITDA is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Retractable Technologies. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Retractable Technologies's current Debt-to-EBITDA is -0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Retractable Technologies stock overvalued right now?
Based on GuruFocus' analysis, Retractable Technologies (RVP) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.76, compared to a current price of $0.68 — trading 10.5% below its estimated fair value. The current Debt-to-EBITDA is -0.10. Retractable Technologies' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Retractable Technologies (RVP), the current Debt-to-EBITDA is -0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Retractable Technologies (RVP) Overvalued in 2026?
Based on GuruFocus' analysis, Retractable Technologies stock appears to be undervalued.
The current stock price of $0.68 is trading 10.5% below its estimated GF Value™ of $0.76.
GuruFocus considers Retractable Technologies to be Modestly Undervalued.
Key valuation signals for RVP:
Debt-to-EBITDA: -0.10
GF Value™: $0.76 vs. price of $0.68 (10.5% below fair value)
No single metric tells the full story. See the RVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Retractable Technologies Inc is engaged in the manufacturing and marketing of safety medical products (predominantly syringes) for the healthcare industry. It has manufacturing facilities in Little Elm, Texas, and uses manufacturers in China as well. Its syringes are well-suited for administering vaccinations. The company's products are VanishPoint Syringe, VanishPoint Insulin Syringes, EasyPoint Needle, EasyPoint Blood Collection Tube with Needle, VanishPoint Blood Collection Set, and VanishPoint IV Catheter. It provides solutions such as Insulin, Immunization, Blood Collection, Allergy, General Purpose, and Infusion.
35GF Score
Get the complete analysis for RVP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVP has been successfully added to your 
